目的探讨包含前S1、前S2和S抗原的新型重组乙型肝炎疫苗(简称SS1S2疫苗)在小鼠中诱导体液和细胞免疫应答的能力以及在无应答小鼠中的免疫原性。方法以不同剂量(2.0、0.5、0.125、0.03μg)的SS1S2疫苗或商品化单S乙型肝炎疫苗(简称S疫苗...目的探讨包含前S1、前S2和S抗原的新型重组乙型肝炎疫苗(简称SS1S2疫苗)在小鼠中诱导体液和细胞免疫应答的能力以及在无应答小鼠中的免疫原性。方法以不同剂量(2.0、0.5、0.125、0.03μg)的SS1S2疫苗或商品化单S乙型肝炎疫苗(简称S疫苗)免疫BALB/c小鼠,于免后1、2、4周时采血,采用ELISA法检测两组疫苗单只小鼠血清的S、前S1和前S2抗体。以SS1S2疫苗或单S疫苗于0和3周时免疫BALB/c小鼠,每只5μg,于每次免疫后1周处死一半小鼠,制备脾脏淋巴细胞,采用ELISPOT法检测分泌IFNγ的细胞毒T淋巴细胞(cytotoxic T lymphocyte,CTL)频数。以单S疫苗于0、2、4周时免疫NIH小鼠,于末次免疫后4周采血,测定S抗体,筛选无应答小鼠。将无应答小鼠分为两组,分别用SS1S2疫苗或单S疫苗加强免疫1次,于免后1个月采血,测定S抗体。结果免后1、2周,2.0、0.5、0.125μg的SS1S2疫苗组S抗体阳转率均高于同剂量的单S疫苗组,且能诱导前S1、前S2抗体产生,而单S疫苗组无前S1、前S2抗体产生;免后4周,两组疫苗的抗体阳转率在总体上继续增加,2.0、0.5、0.125μg的SS1S2疫苗组S抗体几何平均滴度(GMT)均高于同剂量的单S疫苗组,且有一定滴度的前S1、前S2抗体,而单S疫苗组无前S1、前S2抗体产生。初免后1、4周,SS1S2疫苗组小鼠IFNγ分泌细胞频数均明显高于单S疫苗组(P<0.05或<0.01)。以0.5μg SS1S2疫苗或单S疫苗对经3剂单S疫苗免疫无应答NIH小鼠进行1次加强免疫后,SS1S2疫苗组小鼠抗体阳转率和GMT均明显高于单S疫苗组(P均<0.01)。结论与商品化单S乙肝疫苗相比,SS1S2疫苗在小鼠中诱导的抗体产生时间较早,抗体阳转率和抗体滴度较高,还能诱导前S1、前S2抗体产生;SS1S2疫苗比单S疫苗诱导了更高水平的特异性CTL应答;在无应答小鼠中能诱导更大比例和更高滴度的保护性抗体产生,表现出更好的免疫原性。展开更多
Occult hepatitis B virus(HBV)infection(OBI)is a challenging pathobiological and clinical issue that has been widely debated for several decades.By definition,OBI is characterized by the persistence of HBV DNA in the l...Occult hepatitis B virus(HBV)infection(OBI)is a challenging pathobiological and clinical issue that has been widely debated for several decades.By definition,OBI is characterized by the persistence of HBV DNA in the liver tissue(and in some cases also in the serum)in the absence of circulating HBV surface antigen(HBsAg).Many epidemiological and molecular studies have indicated that OBI is an important risk factor for hepatocellular carcinoma(HCC)development.OBI may exert direct pro-oncogenic effects through the activation of the same oncogenic mechanisms that are activated in the course of an HBsAg-positive infection.Indeed,in OBI as in HBV-positive infection,HBV DNA can persist in the hepatocytes both integrated into the host genome as well as free episome,and may maintain the capacity to produce proteins-mainly X protein and truncated preS-S protein-provided with potential transforming properties.Furthermore,OBI may indirectly favor HCC development.It has been shown that the persistence of very low viral replicative activity during OBI may induce mild liver necro-inflammation continuing for life,and substantial clinical evidence indicates that OBI canaccelerate the progression of liver disease towards cirrhosis that is considered the most important risk factor for HCC development.展开更多
目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初...目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初治诊断为原发性CD5+DLBCL标本57例,采用HE染色、免疫组织化学技术及荧光原位杂交(FISH)法,检测原发性CD5+DLBCL中C-MYC、bcl-2、bcl-6蛋白的表达情况,并分析其与临床病理特征之间的关系。结果57例原发性CD5+DLBCL中,男性27例,女性30例,发病年龄35~99岁。C-MYC、bcl-2、bcl-6蛋白表达阳性率分别为50.9%(29/57)、84.2%(48/57)、75.4%(43/57),其中C-MYC和bcl-2双表达阳性率为40.4%(23/57);其在患者性别、临床分期、血清乳酸脱氢酶(LDH)水平、β2微球蛋白水平、国际预后指数(IPI)评分、B症状、骨髓侵犯和中枢神经系统(CNS)复发等临床特征之间差异无统计学意义(P>0.05);单因素生存分析显示:C-MYC阴性患者中位总生存率显著高于阳性患者(P=0.010),双表达阴性患者中位总生存率显著高于阳性患者(P=0.008),bcl-6阳性患者中位总生存率显著高于阴性患者,差异具有统计学意义(P=0.021),bcl-2蛋白表达与预后无明显相关性(P>0.05);Cox模型多因素分析显示,C-MYC蛋白表达可作为原发性CD5+DLBCL患者总生存率的独立预测指标(P=0.034)。结论C-MYC、bcl-2、bcl-6蛋白在原发性CD5+DLBCL的预后价值中,bcl-2表达对预后无影响,bcl-6阳性组预后较好,C-MYC蛋白表达可作为预测原发性CD5+DLBCL患者预后的独立有效指标,但对于原发性CD5+DLBCL患者中,C-MYC、bcl-2及bcl-6蛋白的表达与C-MYC、bcl-2及bcl-6基因重排之间的关系,还有待扩大样本量进一步深入探讨。展开更多
AIM: To investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer.METHODS: The patients with preoperative tumormakers [Carcinoembryonic antigen, Carbohydrate antigen(CA) 19-...AIM: To investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer.METHODS: The patients with preoperative tumormakers [Carcinoembryonic antigen, Carbohydrate antigen(CA) 19-9, and CA 125] and elective gastrectomy between January 2000 and December 2009 at Chungbuk National University Hospital were enrolled in this study. We analyzed the relationship among the tumor makers, curative resection and recurrence, retrospectively.RESULTS: Among the 679 patients with gastric cancer, curative resection was 93.6%(n = 636) and noncurative resection was 6.4%(n = 43). The independent risk factors for the non-curative resection were tumor location and the positivity of preoperative serum CA 19-9 and CA 125 levels. After curative resection, the independent prognostic risk factors for recurrence in curative resection were gender, stage, and preoperative increased serum CA 125 level(HR = 2.431, P =0.020), in a multivariate analysis. CONCLUSION: Preoperative CA 125 is a useful predictive biomarker for curative resection and prognostic biomarker for recurrence in gastric cancer patients.展开更多
文摘目的探讨包含前S1、前S2和S抗原的新型重组乙型肝炎疫苗(简称SS1S2疫苗)在小鼠中诱导体液和细胞免疫应答的能力以及在无应答小鼠中的免疫原性。方法以不同剂量(2.0、0.5、0.125、0.03μg)的SS1S2疫苗或商品化单S乙型肝炎疫苗(简称S疫苗)免疫BALB/c小鼠,于免后1、2、4周时采血,采用ELISA法检测两组疫苗单只小鼠血清的S、前S1和前S2抗体。以SS1S2疫苗或单S疫苗于0和3周时免疫BALB/c小鼠,每只5μg,于每次免疫后1周处死一半小鼠,制备脾脏淋巴细胞,采用ELISPOT法检测分泌IFNγ的细胞毒T淋巴细胞(cytotoxic T lymphocyte,CTL)频数。以单S疫苗于0、2、4周时免疫NIH小鼠,于末次免疫后4周采血,测定S抗体,筛选无应答小鼠。将无应答小鼠分为两组,分别用SS1S2疫苗或单S疫苗加强免疫1次,于免后1个月采血,测定S抗体。结果免后1、2周,2.0、0.5、0.125μg的SS1S2疫苗组S抗体阳转率均高于同剂量的单S疫苗组,且能诱导前S1、前S2抗体产生,而单S疫苗组无前S1、前S2抗体产生;免后4周,两组疫苗的抗体阳转率在总体上继续增加,2.0、0.5、0.125μg的SS1S2疫苗组S抗体几何平均滴度(GMT)均高于同剂量的单S疫苗组,且有一定滴度的前S1、前S2抗体,而单S疫苗组无前S1、前S2抗体产生。初免后1、4周,SS1S2疫苗组小鼠IFNγ分泌细胞频数均明显高于单S疫苗组(P<0.05或<0.01)。以0.5μg SS1S2疫苗或单S疫苗对经3剂单S疫苗免疫无应答NIH小鼠进行1次加强免疫后,SS1S2疫苗组小鼠抗体阳转率和GMT均明显高于单S疫苗组(P均<0.01)。结论与商品化单S乙肝疫苗相比,SS1S2疫苗在小鼠中诱导的抗体产生时间较早,抗体阳转率和抗体滴度较高,还能诱导前S1、前S2抗体产生;SS1S2疫苗比单S疫苗诱导了更高水平的特异性CTL应答;在无应答小鼠中能诱导更大比例和更高滴度的保护性抗体产生,表现出更好的免疫原性。
文摘Occult hepatitis B virus(HBV)infection(OBI)is a challenging pathobiological and clinical issue that has been widely debated for several decades.By definition,OBI is characterized by the persistence of HBV DNA in the liver tissue(and in some cases also in the serum)in the absence of circulating HBV surface antigen(HBsAg).Many epidemiological and molecular studies have indicated that OBI is an important risk factor for hepatocellular carcinoma(HCC)development.OBI may exert direct pro-oncogenic effects through the activation of the same oncogenic mechanisms that are activated in the course of an HBsAg-positive infection.Indeed,in OBI as in HBV-positive infection,HBV DNA can persist in the hepatocytes both integrated into the host genome as well as free episome,and may maintain the capacity to produce proteins-mainly X protein and truncated preS-S protein-provided with potential transforming properties.Furthermore,OBI may indirectly favor HCC development.It has been shown that the persistence of very low viral replicative activity during OBI may induce mild liver necro-inflammation continuing for life,and substantial clinical evidence indicates that OBI canaccelerate the progression of liver disease towards cirrhosis that is considered the most important risk factor for HCC development.
文摘目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初治诊断为原发性CD5+DLBCL标本57例,采用HE染色、免疫组织化学技术及荧光原位杂交(FISH)法,检测原发性CD5+DLBCL中C-MYC、bcl-2、bcl-6蛋白的表达情况,并分析其与临床病理特征之间的关系。结果57例原发性CD5+DLBCL中,男性27例,女性30例,发病年龄35~99岁。C-MYC、bcl-2、bcl-6蛋白表达阳性率分别为50.9%(29/57)、84.2%(48/57)、75.4%(43/57),其中C-MYC和bcl-2双表达阳性率为40.4%(23/57);其在患者性别、临床分期、血清乳酸脱氢酶(LDH)水平、β2微球蛋白水平、国际预后指数(IPI)评分、B症状、骨髓侵犯和中枢神经系统(CNS)复发等临床特征之间差异无统计学意义(P>0.05);单因素生存分析显示:C-MYC阴性患者中位总生存率显著高于阳性患者(P=0.010),双表达阴性患者中位总生存率显著高于阳性患者(P=0.008),bcl-6阳性患者中位总生存率显著高于阴性患者,差异具有统计学意义(P=0.021),bcl-2蛋白表达与预后无明显相关性(P>0.05);Cox模型多因素分析显示,C-MYC蛋白表达可作为原发性CD5+DLBCL患者总生存率的独立预测指标(P=0.034)。结论C-MYC、bcl-2、bcl-6蛋白在原发性CD5+DLBCL的预后价值中,bcl-2表达对预后无影响,bcl-6阳性组预后较好,C-MYC蛋白表达可作为预测原发性CD5+DLBCL患者预后的独立有效指标,但对于原发性CD5+DLBCL患者中,C-MYC、bcl-2及bcl-6蛋白的表达与C-MYC、bcl-2及bcl-6基因重排之间的关系,还有待扩大样本量进一步深入探讨。
基金Supported by Research grant of Chungbuk National Universityin 2013
文摘AIM: To investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer.METHODS: The patients with preoperative tumormakers [Carcinoembryonic antigen, Carbohydrate antigen(CA) 19-9, and CA 125] and elective gastrectomy between January 2000 and December 2009 at Chungbuk National University Hospital were enrolled in this study. We analyzed the relationship among the tumor makers, curative resection and recurrence, retrospectively.RESULTS: Among the 679 patients with gastric cancer, curative resection was 93.6%(n = 636) and noncurative resection was 6.4%(n = 43). The independent risk factors for the non-curative resection were tumor location and the positivity of preoperative serum CA 19-9 and CA 125 levels. After curative resection, the independent prognostic risk factors for recurrence in curative resection were gender, stage, and preoperative increased serum CA 125 level(HR = 2.431, P =0.020), in a multivariate analysis. CONCLUSION: Preoperative CA 125 is a useful predictive biomarker for curative resection and prognostic biomarker for recurrence in gastric cancer patients.
